Nuvation Bio saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Nuvation Bio’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nuvation Bio has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 20% filings and 100% grants. The World Intellectual Property Organization(WIPO), United States(US), and Chile(CL) patent Office are among the top ten patent offices where Nuvation Bio is filings its patents. Among the top granted patent authorities, Nuvation Bio has 100% of its grants in United States(US).
Roche could be the strongest competitor for Nuvation Bio
Patents related to rare diseases lead Nuvation Bio's portfolio
Nuvation Bio has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Breast cancer related patents lead Nuvation Bio portfolio followed by head and neck carcinoma, and neuroblastoma
Nuvation Bio has highest number of patents in breast cancer followed by head and neck carcinoma, neuroblastoma, thyroid cancer, and gastric cancer. For breast cancer, nearly 2% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of Nuvation Bio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

